CDA-II, a urinary preparation, induces growth arrest and apoptosis of human leukemia cells through inactivation of nuclear factor-kappaB in a caspase-dependent manner

Food and Chemical Toxicology

Volumn 47, Issue 1, 2009, Pages 40-49

  Huang, Jian ^a,b,c   Yang, Min ^a,b,c   Liu, Hui ^a,b,c   Jin, Jie ^a,b,c  

^a ZHEJIANG UNIVERSITY   (China)

^b ZHEJIANG UNIVERSITY   (China)

^c BEIJING HOSPITAL   (China)

Author keywords

Acute myeloid leukemia; Apoptosis; CDA II; Nuclear factor B; Xenograft

Indexed keywords

ANTINEOPLASTIC AGENT; BENZYLOXYCARBONYLVALYLALANYLASPARTYL FLUOROMETHYL KETONE; CASPASE; CASPASE 3; CASPASE 9; CELL DIFFERENTIATION AGENT II; I KAPPA B; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE; PROTEIN BAX; PROTEIN BCL 2; PROTEIN MCL 1; UNCLASSIFIED DRUG; X LINKED INHIBITOR OF APOPTOSIS;

ACUTE GRANULOCYTIC LEUKEMIA; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CANCER CELL CULTURE; CANCER INHIBITION; CANCER SURVIVAL; CELL CYCLE ARREST; CELL LINE; CELL MEMBRANE DEPOLARIZATION; CONTROLLED STUDY; DOSE RESPONSE; DOWN REGULATION; DRUG CYTOTOXICITY; DRUG ISOLATION; ENZYME ACTIVATION; ENZYME INACTIVATION; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; MALE; MITOCHONDRIAL MEMBRANE; MOUSE; NONHUMAN; PERIPHERAL BLOOD MONONUCLEAR CELL; SCID MOUSE; SURVIVAL TIME; THERAPY EFFECT; TREATMENT OUTCOME; TREATMENT RESPONSE; XENOGRAFT;

ANIMALS; ANTINEOPLASTIC AGENTS; APOPTOSIS; BCL-2-ASSOCIATED X PROTEIN; BONE MARROW CELLS; CASPASES; CELL LINE, TUMOR; COLLAGEN TYPE XI; DOSE-RESPONSE RELATIONSHIP, DRUG; GENE EXPRESSION REGULATION; GRANULOCYTE PRECURSOR CELLS; HUMANS; LEUKEMIA, MYELOID, ACUTE; LEUKOCYTES, MONONUCLEAR; MEMBRANE POTENTIAL, MITOCHONDRIAL; MICE; MICE, SCID; NEOPLASMS, EXPERIMENTAL; NF-KAPPA B; PEPTIDES; PHENYLACETATES; PROTO-ONCOGENE PROTEINS C-BCL-2;

MUS;

EID: 58149293795     PISSN: 02786915     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.fct.2008.08.001     Document Type: Article

References (41)

1. Armstrong J.S. Mitochondria: a target for cancer therapy. Br. J. Pharmacol. 147 (2006) 239-248
2. Badria F., Mabed M., Khafagy W., and Abou-Zeid L. Potential utility of antineoplaston A-10 levels in breast cancer. Cancer Lett. 155 (2000) 67-70
3. Burkle A. Physiology and pathophysiology of poly(ADP-ribosyl)ation. Bioessays 23 (2001) 795-806
4. Burzynski S.R. Antineoplastons: history of the research (I). Drugs Exp. Clin. Res. 12 Suppl. 1 (1986) 1-9
5. Burzynski S.R. The present state of antineoplaston research (1). Integr. Cancer Ther. 3 (2004) 47-58
6. Burzynski S.R., Janicki T.J., Weaver R.A., and Burzynski B. Targeted therapy with antineoplastons A10 and AS2-1 of high-grade, recurrent, and progressive brainstem glioma. Integr. Cancer Ther. 5 (2006) 40-47
7. Carter B.Z., Mak D.H., Schober W.D., McQueen T., Harris D., Estrov Z., Evans R.L., and Andreeff M. Triptolide induces caspase-dependent cell death mediated via the mitochondrial pathway in leukemic cells. Blood 108 (2006) 630-637
8. Carter B.Z., Milella M., Tsao T., McQueen T., Schober W.D., Hu W., Dean N.M., Steelman L., McCubrey J.A., and Andreeff M. Regulation and targeting of antiapoptotic XIAP in acute myeloid leukemia. Leukemia 17 (2003) 2081-2089
9. Catz S.D., and Johnson J.L. Transcriptional regulation of bcl-2 by nuclear factor kappa B and its significance in prostate cancer. Oncogene 20 (2001) 7342-7351
10. Del Poeta G., Venditti A., Del Principe M.I., Maurillo L., Buccisano F., Tamburini A., Cox M.C., Franchi A., Bruno A., Mazzone C., Panetta P., Suppo G., Masi M., and Amadori S. Amount of spontaneous apoptosis detected by Bax/Bcl-2 ratio predicts outcome in acute myeloid leukemia (AML). Blood 101 (2003) 2125-2131
11. Dlugosz P.J., Billen L.P., Annis M.G., Zhu W., Zhang Z., Lin J., Leber B., and Andrews D.W. Bcl-2 changes conformation to inhibit Bax oligomerization. EMBO J. 25 (2006) 2287-2296
12. Fischer U., and Schulze-Osthoff K. Apoptosis-based therapies and drug targets. Cell Death Differ. 12 Suppl. 1 (2005) 942-961
13. Fujii T., Yokoyama G., Takahashi H., Namoto R., Nakagawa S., Toh U., Kage M., Shirouzu K., and Kuwano M. Preclinical studies of molecular-targeting diagnostic and therapeutic strategies against breast cancer. Breast Cancer 15 (2008) 73-78
14. Gomez-Bougie P., Wuilleme-Toumi S., Menoret E., Trichet V., Robillard N., Philippe M., Bataille R., and Amiot M. Noxa up-regulation and Mcl-1 cleavage are associated to apoptosis induction by bortezomib in multiple myeloma. Cancer Res. 67 (2007) 5418-5424
15. Guzman M.L., Neering S.J., Upchurch D., Grimes B., Howard D.S., Rizzieri D.A., Luger S.M., and Jordan C.T. Nuclear factor-kappaB is constitutively activated in primitive human acute myelogenous leukemia cells. Blood 98 (2001) 2301-2307
16. Han J., Goldstein L.A., Gastman B.R., and Rabinowich H. Interrelated roles for Mcl-1 and BIM in regulation of TRAIL-mediated mitochondrial apoptosis. J. Biol. Chem. 281 (2006) 10153-10163
17. Hehir K.M., Baguisi A., Pennington S.E., Bates J.M., and DiTullio P.A. A potential antitumor peptide therapeutic derived from antineoplastic urinary protein. Peptides 25 (2004) 543-549
18. Hughes P., Bouillet P., and Strasser A. Role of Bim and other Bcl-2 family members in autoimmune and degenerative diseases. Curr. Dir. Autoimmun. 9 (2006) 74-94
19. Jin J., Jiang D.Z., Mai W.Y., Meng H.T., Qian W.B., Tong H.Y., Huang J., Mao L.P., Tong Y., Wang L., Chen Z.M., and Xu W.L. Homoharringtonine in combination with cytarabine and aclarubicin resulted in high complete remission rate after the first induction therapy in patients with de novo acute myeloid leukemia. Leukemia 20 (2006) 1361-1367
20. Kaufmann S.H., Karp J.E., Svingen P.A., Krajewski S., Burke P.J., Gore S.D., and Reed J.C. Elevated expression of the apoptotic regulator Mcl-1 at the time of leukemic relapse. Blood 91 (1998) 991-1000
21. Lakhani N.J., Sparreboom A., Xu X., Veenstra T.D., Venitz J., Dahut W.L., and Figg W.D. Characterization of in vitro and in vivo metabolic pathways of the investigational anticancer agent 2-methoxyestradiol. J. Pharm. Sci. 96 (2007) 1821-1831
22. Lee R., and Collins T. Nuclear factor-kappaB and cell survival: IAPs call for support. Circ. Res. 88 (2001) 262-264
23. Liau M.C., Szopa M., Burzynski B., and Burzynski S.R. Quantitative assay of plasma and urinary peptides as an aid for the evaluation of cancer patients undergoing antineoplaston therapy. Drugs Exper. Clin. Res. 13 Suppl. 1 (1987) 61-70
24. Liau M.C., Lee S.S., and Burzynski S.R. Differentiation inducing components of antineo-plaston A5. In: Kuemmerle H.P. (Ed). Advances in Experimental and Clinical Chemotherapy (1988), Ecomed Verlagsgesellschaft, Munich 9-25
25. Liau M.C., and Burzynski S.R. Separation of active anticancer components of antineoplaston A2, A3 and A5. Int. J. Tissue React. 7 Suppl. (1990) 1-17
26. Lin W.C., Wu Y.W., Lai T.Y., and Liau M.C. Effect of CDA-II, urinary preparation, on lipofuscin, lipid peroxidation and antioxidant systems in young and middle-aged rat brain. Am. J. Chin. Med. 29 (2001) 91-99
27. Lin W.C., Liao Y.C., Liau M.C., Lii C.K., and Sheen L.Y. Inhibitory effect of CDA-II, a urinary preparation, on aflatoxin B(1)-induced oxidative stress and DNA damage in primary cultured rat hepatocytes. Food Chem. Toxicol. 44 (2006) 546-551
28. Linder-Stragliotto C., Strander H., Munck-Wikland E., and Sten-Linder M. Low levels of endostatin in the urine from patients with malignant disease. Tumour Biol. 23 (2002) 222-227
29. Masood R., McGarvey M.E., Zheng T., Cai J., Arora N., Smith D.L., Sloane N., and Gill P.S. Antineoplastic urinary protein inhibits Kaposi's sarcoma and angiogenesis in vitro and in vivo. Blood 93 (1999) 1038-1044
30. Moshynska O., Sankaran K., Pahwa P., and Saxena A. Prognostic significance of a short sequence insertion in the MCL-1 promoter in chronic lymphocytic leukemia. J. Natl. Cancer Inst. 96 (2004) 673-682
31. Ogata Y., Tsuda H., Matono K., Kumabe T., Saitsu H., Hara H., Akagi Y., Araki Y., Sata M., and Shirouzu K. Long-term survival following treatment with antineoplastons for colon cancer with unresectable multiple liver metastases: report of a case. Surg. Today 33 (2003) 448-453
32. Ryningen A., Ersvaer E., Oyan A.M., Kalland K.H., Vintermyr O.K., Gjertsen B.T., and Bruserud O. Stress-induced in vitro apoptosis of native human acute myelogenous leukemia (AML) cells shows a wide variation between patients and is associated with low BCL-2:Bax ratio and low levels of heat shock protein 70 and 90. Leuk. Res. 30 (2006) 1531-1540
33. Sedletska Y., Giraud-Panis M.J., and Malinge J.M. Cisplatin is a DNA-damaging antitumour compound triggering multifactorial biochemical responses in cancer cells: importance of apoptotic pathways. Curr. Med. Chem. Anticancer Agents 5 (2005) 251-265
34. Stehlik C., de Martin R., Kumabashiri I., Schmid J.A., Binder B.R., and Lipp J. Nuclear factor (NF)-kappaB-regulated X-chromosome-linked iap gene expression protects endothelial cells from tumor necrosis factor alpha-induced apoptosis. J. Exp. Med. 188 (1998) 211-216
35. Sturm I., Petrowsky H., Volz R., Lorenz M., Radetzki S., Hillebrand T., Wolff G., Hauptmann S., Dorken B., and Daniel P.T. Analysis of p53/BAX/p16(ink4a/CDKN2) in esophageal squamous cell carcinoma: high BAX and p16(ink4a/CDKN2) identifies patients with good prognosis. J. Clin. Oncol. 19 (2001) 2272-2281
36. Sun Y. Targeting E3 ubiquitin ligases for cancer therapy. Cancer Biol. Ther. 2 (2003) 623-629
37. Tong W.M., Cortes U., and Wang Z.Q. Poly(ADP-ribose) polymerase: a guardian angel protecting the genome and suppressing tumorigenesis. Biochim. Biophys. Acta 1552 (2001) 27-37
38. Wang L., Zhao W.L., Yan J.S., Liu P., Sun H.P., Zhou G.B., Weng Z.Y., Wu W.L., Weng X.Q., Sun X.J., Chen Z., Sun H.D., and Chen S.J. Eriocalyxin B induces apoptosis of t(8;21) leukemia cells through NF-kappaB and MAPK signaling pathways and triggers degradation of AML1-ETO oncoprotein in a caspase-3-dependent manner. Cell Death Differ. 14 (2006) 306-317
39. Woo M., Hakem R., Soengas M.S., Duncan G.S., Shahinian A., Kagi D., Hakem A., McCurrach M., Khoo W., Kaufman S.A., Senaldi G., Howard T., Lowe S.W., and Mak T.W. Essential contribution of caspase 3/CPP32 to apoptosis and its associated nuclear changes. Genes Dev. 12 (1998) 806-819
40. Yao C.J., Lai G.M., Chan C.F., Yang Y.Y., Liu F.C., and Chuang S.E. Differentiation of pheochromocytoma PC12 cells induced by human urine extract and the involvement of the extracellular signal-regulated kinase signaling pathway. J. Alter. Compl. Med. 11 (2005) 903-908
41. Zhivotovsky B., and Orrenius S. Carcinogenesis and apoptosis: paradigms and paradoxes. Carcinogenesis 27 (2006) 1939-1945